As power shifts hands in Washington, a top analyst predicts an unavoidable war over rising drug prices
The drug industry has two powerful reasons for bucking President Donald Trump’s campaign to cap and lower drug prices. As Bernstein’s Ronny Gal sees it, they have to keep drug prices moving upward to meet Wall Street’s expectations on their numbers.
Threatening to really shove prices north is also a good bargaining chip for the price negotiations to come in Washington DC, he adds. And the industry may soon have a longtime ally among the Democrats in a key position to influence any drug pricing legislation to come.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.